Hyperfine, Inc. (NASDAQ: HYPR)

Hyperfine, Inc. is an innovative health technology business focused on revolutionizing patient care through AI powered portable ultra low field magnetic resonance brain imaging. The company’s flagship product is the Swoop® system which creates diagnostic quality brain images at a fraction of the magnetic field strength used by conventional MRI scanners. Designed for use at the point of care the Swoop® system can be moved easily within hospitals clinics and physician offices without requiring specialized rooms or cryogenic cooling. The technology integrates an easy to use tablet based interface and proprietary AI software that enhances image quality while reducing scan time. By providing bedside imaging the Swoop® system aims to increase access to neuroimaging for patients in critical care emergency departments and outpatient neurology settings. Hyperfine, Inc. was founded in 2014 and has expanded its regulatory clearances and patent portfolio to support global commercialization.

Hyperfine, Inc. generates revenue primarily through the sale of the Swoop® system accompanied by an annual software service and support agreement. Under this model customers purchase the hardware and then enter into a multi year contract that provides software updates technical assistance and access to a cloud based picture archiving and communication system. The agreements are typically offered in thirty six month or sixty month terms with options for upfront payment of the device followed by annual service fees or a fully bundled annual payment. In some cases the system is sold without a service agreement though the majority of placements include the recurring support component. The company also earns income from the sale of accessories and from fees related to training and implementation services. Recurring revenue from service contracts is expected to improve gross margin as the installed base grows and as pricing is adjusted annually.

Hyperfine, Inc. occupies a distinctive niche within the broader magnetic resonance imaging market by offering the first FDA cleared AI powered portable ultra low field brain scanner. While major competitors such as General Electric Siemens Philips and Hitachi dominate the high field MRI landscape Hyperfine, Inc. focuses on underserved settings where conventional scanners are impractical due to cost size or infrastructure requirements. The company’s competitive advantages include its proprietary magnet design its noise cancellation technology and its deep learning powered image reconstruction which together deliver usable images at low field strength. A substantial patent estate with nearly two hundred issued patents and many pending applications further protects its technology. By positioning its product as a complement rather than a replacement for traditional MRI the firm seeks to augment existing capacity and improve workflow efficiency in intensive care units emergency departments and neurology offices.

The company serves hospitals health systems office based neurology practices and international healthcare providers. In the United States its initial focus has been on critical care units emergency departments and hospital based clinics where the Swoop® system enables bedside neuroimaging without patient transport. More recently Hyperfine, Inc. has expanded into the outpatient neurology office market allowing physicians to perform magnetic resonance examinations during routine visits. Outside the United States the firm relies on a network of distributors to sell and support the Swoop® system in countries such as Canada the United Kingdom Australia New Zealand India and various European and Middle Eastern markets. Specific customer names are not disclosed in the filing but the target audience includes acute care facilities academic medical centers community hospitals and private neurology clinics.